Bacteria-made anti-inflammatory fats
Bacterial anti-inflammatory lipid mediators
Researchers are looking at fats made by bacteria that may calm harmful inflammation during infections and in the gut.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11163298 on NIH RePORTER |
What this research studies
This project looks at special fatty molecules (10-hydroxy-fatty acids, or hFAs) made by bacteria through an enzyme called OhyA and how those molecules can dial down the immune system's early inflammatory response to bacterial signals. The team uses bacterial genetics, lab cell experiments, and mouse infection models to see whether bacteria-produced hFAs reduce inflammation and help bacteria persist. They will map how hFAs interact with immune signaling pathways and study hFAs from gut microbes and the pathogen Staphylococcus aureus. The work aims to explain how some microbes promote a tolerant environment in the gut and why OhyA helps S. aureus cause infections.
Who could benefit from this research
Good fit: People with bacterial infections (for example recurrent Staphylococcus aureus infections) or chronic inflammatory gut conditions could be the kinds of patients who might eventually benefit from related treatments.
Not a fit: Patients whose problems are purely viral, genetic, or non-inflammatory pain conditions are unlikely to get direct benefit from this line of work in the near term.
Why it matters
Potential benefit: If successful, this work could point to new therapies that mimic or harness bacterial hFAs to reduce harmful inflammation in infections and certain gut inflammatory conditions.
How similar studies have performed: Early laboratory and mouse studies provide preliminary evidence that these bacterial hFAs can reduce inflammation, but translating that into human therapies is still new and not yet proven.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Radka, Christopher David — University of Kentucky
- Study coordinator: Radka, Christopher David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.